TY - JOUR
T1 - Algorithmic surveillance of i CU patients with acute respiratory distress syndrome (ASIC)
T2 - Protocol for a multicentre stepped-wedge cluster randomised quality improvement strategy
AU - Marx, Gernot
AU - Bickenbach, Johannes
AU - Fritsch, Sebastian Johannes
AU - Kunze, Julian Benedict
AU - Maassen, Oliver
AU - Deffge, Saskia
AU - Kistermann, Jennifer
AU - Haferkamp, Silke
AU - Lutz, Irina
AU - Voellm, Nora Kristiana
AU - Lowitsch, Volker
AU - Polzin, Richard
AU - Sharafutdinov, Konstantin
AU - Mayer, Hannah
AU - Kuepfer, Lars
AU - Burghaus, Rolf
AU - Schmitt, Walter
AU - Lippert, Joerg
AU - Riedel, Morris
AU - Barakat, Chadi
AU - Stollenwerk, André
AU - Fonck, Simon
AU - Putensen, Christian
AU - Zenker, Sven
AU - Erdfelder, Felix
AU - Grigutsch, Daniel
AU - Kram, Rainer
AU - Beyer, Susanne
AU - Kampe, Knut
AU - Gewehr, Jan Erik
AU - Salman, Friederike
AU - Juers, Patrick
AU - Kluge, Stefan
AU - Tiller, Daniel
AU - Wisotzki, Emilia
AU - Gross, Sebastian
AU - Homeister, Lorenz
AU - Bloos, Frank
AU - Scherag, André
AU - Ammon, Danny
AU - Mueller, Susanne
AU - Palm, Julia
AU - Simon, Philipp
AU - Jahn, Nora
AU - Loeffler, Markus
AU - Wendt, Thomas
AU - Schuerholz, Tobias
AU - Groeber, Petra
AU - Schuppert, Andreas
N1 - © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Introduction The acute respiratory distress syndrome (ARDS) is a highly relevant entity in critical care with mortality rates of 40%. Despite extensive scientific efforts, outcome-relevant therapeutic measures are still insufficiently practised at the bedside. Thus, there is a clear need to adhere to early diagnosis and sufficient therapy in ARDS, assuring lower mortality and multiple organ failure. Methods and analysis In this quality improvement strategy (QIS), a decision support system as a mobile application (ASIC app), which uses available clinical real-time data, is implemented to support physicians in timely diagnosis and improvement of adherence to established guidelines in the treatment of ARDS. ASIC is conducted on 31 intensive care units (ICUs) at 8 German university hospitals. It is designed as a multicentre stepped-wedge cluster randomised QIS. ICUs are combined into 12 clusters which are randomised in 12 steps. After preparation (18 months) and a control phase of 8 months for all clusters, the first cluster enters a roll-in phase (3 months) that is followed by the actual QIS phase. The remaining clusters follow in month wise steps. The coprimary key performance indicators (KPIs) consist of the ARDS diagnostic rate and guideline adherence regarding lung-protective ventilation. Secondary KPIs include the prevalence of organ dysfunction within 28 days after diagnosis or ICU discharge, the treatment duration on ICU and the hospital mortality. Furthermore, the user acceptance and usability of new technologies in medicine are examined. To show improvements in healthcare of patients with ARDS, differences in primary and secondary KPIs between control phase and QIS will be tested. Ethics and dissemination Ethical approval was obtained from the independent Ethics Committee (EC) at the RWTH Aachen Faculty of Medicine (local EC reference number: EK 102/19) and the respective data protection officer in March 2019. The results of the ASIC QIS will be presented at conferences and published in peer-reviewed journals. Trial registration number DRKS00014330.
AB - Introduction The acute respiratory distress syndrome (ARDS) is a highly relevant entity in critical care with mortality rates of 40%. Despite extensive scientific efforts, outcome-relevant therapeutic measures are still insufficiently practised at the bedside. Thus, there is a clear need to adhere to early diagnosis and sufficient therapy in ARDS, assuring lower mortality and multiple organ failure. Methods and analysis In this quality improvement strategy (QIS), a decision support system as a mobile application (ASIC app), which uses available clinical real-time data, is implemented to support physicians in timely diagnosis and improvement of adherence to established guidelines in the treatment of ARDS. ASIC is conducted on 31 intensive care units (ICUs) at 8 German university hospitals. It is designed as a multicentre stepped-wedge cluster randomised QIS. ICUs are combined into 12 clusters which are randomised in 12 steps. After preparation (18 months) and a control phase of 8 months for all clusters, the first cluster enters a roll-in phase (3 months) that is followed by the actual QIS phase. The remaining clusters follow in month wise steps. The coprimary key performance indicators (KPIs) consist of the ARDS diagnostic rate and guideline adherence regarding lung-protective ventilation. Secondary KPIs include the prevalence of organ dysfunction within 28 days after diagnosis or ICU discharge, the treatment duration on ICU and the hospital mortality. Furthermore, the user acceptance and usability of new technologies in medicine are examined. To show improvements in healthcare of patients with ARDS, differences in primary and secondary KPIs between control phase and QIS will be tested. Ethics and dissemination Ethical approval was obtained from the independent Ethics Committee (EC) at the RWTH Aachen Faculty of Medicine (local EC reference number: EK 102/19) and the respective data protection officer in March 2019. The results of the ASIC QIS will be presented at conferences and published in peer-reviewed journals. Trial registration number DRKS00014330.
KW - adult intensive & critical care
KW - health informatics
KW - information technology
KW - respiratory medicine (see thoracic medicine)
KW - Intensive Care Units
KW - Multicenter Studies as Topic
KW - Quality Improvement
KW - Humans
KW - Respiratory Distress Syndrome/diagnosis
KW - Critical Care
KW - Respiration, Artificial
UR - http://www.scopus.com/inward/record.url?scp=85103944677&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-045589
DO - 10.1136/bmjopen-2020-045589
M3 - Article
C2 - 34550901
AN - SCOPUS:85103944677
SN - 2044-6055
VL - 11
SP - e045589
JO - BMJ Open
JF - BMJ Open
IS - 4
M1 - e045589
ER -